Highlights
KLSE: BSTEAD (2771)       BOUSTEAD HOLDINGS BHD MAIN : Industrial Products
Last Price Today's Change   Day's Range   Trading Volume
0.85   +0.005 (0.59%)  0.85 - 0.855  243,500
Analyze this stock with MQ Trader system

Financials


Market Cap: 1,723 Million

Market Cap 1,723 Million
NOSH 2,027 Million

Latest Audited Result:  31-Dec-2017

Latest Audited Result: 31-Dec-2017
Announcement Date 14-Mar-2018
Next Audited Result: 31-Dec-2018
Est. Ann. Date: 14-Mar-2019
Est. Ann. Due Date: 29-Jun-2019

Latest Quarter:  30-Sep-2019 [#3]

Latest Quarter: 30-Sep-2019 [#3]
Announcement Date 29-Nov-2019
Next Quarter: 31-Dec-2019
Est. Ann. Date: 28-Feb-2020
Est. Ann. Due Date: 29-Feb-2020
QoQ | YoY   -737.86%  |    -2,223.29%

Annual (Unaudited) ( EPS: -23.15, P/E: -3.67 )

Revenue | NP to SH 10,186,400  |  -469,200
RPS | P/RPS 502.54 Cent  |  0.17
EPS | P/E | EY -23.15 Cent  |  -3.67  |  -27.23%
DPS | DY | Payout % 5.00 Cent  |  5.88%  |  - %
NAPS | P/NAPS 2.65  |  0.32
YoY   -201.56%
NP Margin | ROE -4.79%  |  -8.74%
F.Y. | Ann. Date 31-Dec-2018  |  28-Feb-2019

T4Q Result ( EPS: -30.00, P/E: -2.83 )

Revenue | NP to SH 10,810,200  |  -608,100
RPS | P/RPS 533.31 Cent  |  0.16
EPS | P/E | EY -30.00 Cent  |  -2.83  |  -35.29%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 2.59  |  0.33
QoQ | YoY   -36.41%  |    -945.76%
NP Margin | ROE -6.08%  |  -11.58%
F.Y. | Ann. Date 30-Sep-2019  |  29-Nov-2019

Annualized Result ( EPS: -10.07, P/E: -8.44 )

Revenue | NP to SH 10,380,666  |  -204,133
RPS | P/RPS 512.12 Cent  |  0.17
EPS | P/E | EY -10.07 Cent  |  -8.44  |  -11.85%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -5,471.93%  |    -978.17%
NP Margin | ROE -1.18%  |  -3.89%
F.Y. | Ann. Date 30-Sep-2019  |  29-Nov-2019


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2019 29-Nov-2019 30-Sep-2019 3 2,734,700 -156,400 -187,500 -155,000 - 5,249,929 - % -6.86% -2.95% 2,027,000 134.91 134.91 -7.65 -7.65 0.00 0.00 2.5900 2.59   -737.86%   -2,223.29% 30-Sep-2019 1.01 0.75 -13.21 0.39 -7.57% 0.00% 29-Nov-2019 0.965 0.72 -12.62 0.37 -7.92% 0.00%
31-Dec-2019 28-Aug-2019 30-Jun-2019 2 2,544,100 118,900 84,100 24,300 - 5,412,090 - % 3.31% 0.45% 2,027,000 125.51 125.51 1.20 1.20 0.00 0.00 2.6700 2.67   208.48%   188.04% 28-Jun-2019 1.09 0.87 90.92 0.41 1.10% 0.00% 28-Aug-2019 1.01 0.80 84.25 0.38 1.19% 0.00%
31-Dec-2019 30-May-2019 31-Mar-2019 1 2,506,700 51,500 11,400 -22,400 - 5,371,550 - % 0.45% -0.42% 2,027,000 123.67 123.67 -1.11 -1.11 0.00 0.00 2.6500 2.65   95.08%   -467.21% 29-Mar-2019 1.27 1.03 -114.92 0.48 -0.87% 0.00% 30-May-2019 1.11 0.90 -100.45 0.42 -1.00% 0.00%
31-Dec-2018 28-Feb-2019 31-Dec-2018 4 3,024,700 -542,400 -565,000 -455,000 - 5,371,550 - % -18.68% -8.47% 2,027,000 149.22 149.22 -22.45 -22.45 0.00 0.00 2.6500 2.65   -6,332.88%   -628.46% 31-Dec-2018 1.41 0.94 -6.28 0.53 -15.92% 0.00% 28-Feb-2019 1.45 0.97 -6.46 0.55 -15.48% 0.00%
31-Dec-2018 30-Nov-2018 30-Sep-2018 3 2,543,000 63,800 40,100 7,300 30,405 6,060,730 416.51% 1.58% 0.12% 2,027,000 125.46 125.46 0.36 0.36 1.50 1.50 2.9900 2.99   126.45%   -97.66% 28-Sep-2018 1.91 1.52 530.35 0.64 0.19% 0.79% 30-Nov-2018 1.48 1.18 410.95 0.49 0.24% 1.01%
31-Dec-2018 29-Aug-2018 30-Jun-2018 2 2,373,700 20,400 -1,300 -27,600 20,270 6,040,460 - % -0.05% -0.46% 2,027,000 117.10 117.10 -1.36 -1.36 1.00 1.00 2.9800 2.98   -552.46%   -146.54% 29-Jun-2018 2.46 2.10 -180.67 0.83 -0.55% 0.41% 29-Aug-2018 2.00 1.71 -146.88 0.67 -0.68% 0.50%
31-Dec-2018 31-May-2018 31-Mar-2018 1 2,245,000 70,300 38,100 6,100 50,675 6,141,809 830.74% 1.70% 0.10% 2,027,000 110.75 110.75 0.30 0.30 2.50 2.50 3.0300 3.03   -92.92%   45.24% 30-Mar-2018 2.54 2.29 844.03 0.84 0.12% 0.98% 31-May-2018 2.42 2.19 804.15 0.80 0.12% 1.03%
31-Dec-2017 28-Feb-2018 31-Dec-2017 4 2,786,800 240,500 174,000 86,100 50,675 5,918,840 58.86% 6.24% 1.45% 2,027,000 137.48 137.48 4.25 4.25 2.50 2.50 2.9200 2.92   -72.44%   -28.67% 29-Dec-2017 2.89 2.10 68.04 0.99 1.47% 0.87% 28-Feb-2018 2.78 2.02 65.45 0.95 1.53% 0.90%
31-Dec-2017 30-Nov-2017 30-Sep-2017 3 2,471,900 643,100 581,400 312,400 60,810 5,898,570 19.47% 23.52% 5.30% 2,027,000 121.95 121.95 15.41 15.41 3.00 3.00 2.9100 2.91   426.81%   610.00% 29-Sep-2017 2.93 2.40 19.01 1.01 5.26% 1.02% 30-Nov-2017 3.00 2.46 19.47 1.03 5.14% 1.00%
31-Dec-2017 30-Aug-2017 30-Jun-2017 2 2,386,200 161,800 127,000 59,300 60,810 5,655,329 102.55% 5.32% 1.05% 2,027,000 117.72 117.72 2.93 2.93 3.00 3.00 2.7900 2.79   1,311.90%   -73.74% 30-Jun-2017 2.63 2.23 89.90 0.94 1.11% 1.14% 30-Aug-2017 2.70 2.29 92.29 0.97 1.08% 1.11%
31-Dec-2017 29-May-2017 31-Mar-2017 1 2,375,200 71,600 40,900 4,200 50,675 5,635,059 1,206.55% 1.72% 0.07% 2,027,000 117.18 117.18 0.21 0.21 2.50 2.50 2.7800 2.78   -96.52%   119.53% 31-Mar-2017 2.77 2.36 -1,403.70 1.39 -0.07% 0.90% 29-May-2017 2.60 2.22 -1,317.55 1.30 -0.08% 0.96%
31-Dec-2016 28-Feb-2017 31-Dec-2016 4 2,422,200 261,200 184,900 120,700 70,945 6,891,800 58.78% 7.63% 1.75% 2,027,000 119.50 119.50 5.95 5.95 3.50 3.50 3.4000 3.40   174.32%   2,773.81% 30-Dec-2016 2.67 2.23 44.84 0.79 2.23% 1.31% 28-Feb-2017 2.83 2.37 47.53 0.83 2.10% 1.24%
31-Dec-2016 30-Nov-2016 30-Sep-2016 3 2,023,400 120,400 93,300 44,000 101,350 6,912,070 230.34% 4.61% 0.64% 2,027,000 99.82 99.82 2.17 2.17 5.00 5.00 3.4100 3.41   -80.51%   633.33% 30-Sep-2016 2.16 2.16 99.51 0.63 1.00% 2.31% 30-Nov-2016 2.19 2.19 100.89 0.64 0.99% 2.28%
31-Dec-2016 24-Aug-2016 30-Jun-2016 2 2,069,000 341,100 301,400 225,800 66,804 7,983,165 29.59% 14.57% 2.83% 1,670,118 123.88 102.07 13.52 11.14 4.00 3.30 4.7800 3.94   1,150.23%   7,686.21% 30-Jun-2016 2.71 2.19 20.04 0.57 4.99% 1.48% 24-Aug-2016 2.25 1.82 16.64 0.47 6.01% 1.78%
31-Dec-2016 25-May-2016 31-Mar-2016 1 1,856,700 36,300 9,500 -21,500 51,682 5,705,769 - % 0.51% -0.38% 1,033,653 179.62 91.60 -2.08 -1.06 5.00 2.55 5.5200 2.81   -611.90%   -21,600.00% 31-Mar-2016 3.93 2.19 -188.94 0.71 -0.53% 1.27% 25-May-2016 2.84 1.58 -136.54 0.51 -0.73% 1.76%
31-Dec-2015 29-Feb-2016 31-Dec-2015 4 2,442,300 49,700 -800 4,200 40,975 5,695,609 975.61% -0.03% 0.07% 1,024,390 238.42 120.49 0.41 0.21 4.00 2.02 5.5600 2.81   -30.00%   -98.60% 31-Dec-2015 4.30 1.80 1,048.78 0.77 0.10% 0.93% 29-Feb-2016 4.08 1.71 995.12 0.73 0.10% 0.98%
31-Dec-2015 30-Nov-2015 30-Sep-2015 3 2,120,300 66,700 46,300 6,000 62,068 5,793,103 1,034.48% 2.18% 0.10% 1,034,482 204.96 104.60 0.58 0.30 6.00 3.06 5.6000 2.86   106.90%   -67.03% 30-Sep-2015 3.95 1.93 681.03 0.71 0.15% 1.52% 30-Nov-2015 4.07 1.99 701.72 0.73 0.14% 1.47%
31-Dec-2015 24-Aug-2015 30-Jun-2015 2 2,207,600 83,300 50,800 2,900 51,785 5,862,142 1,785.71% 2.30% 0.05% 1,035,714 213.15 108.91 0.28 0.14 5.00 2.55 5.6600 2.89   2,800.00%   -93.60% 30-Jun-2015 4.15 1.95 1,482.14 0.73 0.07% 1.20% 24-Aug-2015 4.10 1.92 1,464.29 0.72 0.07% 1.22%
31-Dec-2015 25-May-2015 31-Mar-2015 1 1,892,300 69,500 43,100 100 50,000 5,659,999 50,000.00% 2.28% 0.00% 1,000,000 189.23 93.35 0.01 0.00 5.00 2.47 5.6600 2.79   -99.97%   -99.85% 31-Mar-2015 4.60 2.43 46,000.00 0.81 0.00% 1.09% 25-May-2015 4.40 2.33 44,000.00 0.78 0.00% 1.14%
31-Dec-2014 27-Feb-2015 31-Dec-2014 4 2,825,900 356,400 324,000 299,000 51,712 5,884,849 17.30% 11.47% 5.08% 1,034,244 273.23 139.41 28.91 14.75 5.00 2.55 5.6900 2.90   1,542.86%   35.79% 31-Dec-2014 4.82 1.76 16.67 0.85 6.00% 1.04% 27-Feb-2015 4.65 1.70 16.08 0.82 6.22% 1.08%
31-Dec-2014 27-Nov-2014 30-Sep-2014 3 2,694,300 86,100 50,200 18,200 62,045 5,604,772 340.91% 1.86% 0.32% 1,034,090 260.55 132.92 1.76 0.90 6.00 3.06 5.4200 2.77   -59.82%   -81.33% 30-Sep-2014 5.00 1.92 284.09 0.92 0.35% 1.20% 27-Nov-2014 4.96 1.90 281.82 0.92 0.35% 1.21%
31-Dec-2014 25-Aug-2014 30-Jun-2014 2 2,588,200 109,900 67,700 45,300 77,568 5,440,137 171.23% 2.62% 0.83% 1,034,246 250.25 127.69 4.38 2.23 7.50 3.83 5.2600 2.68   -32.08%   -25.98% 30-Jun-2014 5.17 2.07 118.04 0.98 0.85% 1.45% 25-Aug-2014 5.13 2.05 117.12 0.98 0.85% 1.46%
31-Dec-2014 26-May-2014 31-Mar-2014 1 2,499,800 133,300 91,400 66,700 77,558 5,222,248 116.28% 3.66% 1.28% 1,034,108 241.73 123.33 6.45 3.29 7.50 3.83 5.0500 2.58   -69.71%   -33.23% 31-Mar-2014 5.42 2.24 84.03 1.07 1.19% 1.38% 26-May-2014 5.36 2.22 83.10 1.06 1.20% 1.40%
31-Dec-2013 27-Feb-2014 31-Dec-2013 4 3,590,300 280,500 228,100 220,200 77,571 5,233,499 35.23% 6.35% 4.21% 1,034,288 347.13 177.12 21.29 10.86 7.50 3.83 5.0600 2.58   125.85%   46.31% 31-Dec-2013 5.62 1.62 26.40 1.11 3.79% 1.33% 27-Feb-2014 5.36 1.54 25.18 1.06 3.97% 1.40%
31-Dec-2013 29-Nov-2013 30-Sep-2013 3 2,700,500 159,200 122,900 97,500 77,545 4,745,758 79.53% 4.55% 2.05% 1,033,934 261.19 133.23 9.43 4.81 7.50 3.83 4.5900 2.34   59.31%   25.16% 30-Sep-2013 5.19 1.99 55.04 1.13 1.82% 1.45% 29-Nov-2013 5.35 2.05 56.73 1.17 1.76% 1.40%
31-Dec-2013 21-Aug-2013 30-Jun-2013 2 2,390,100 93,100 74,700 61,200 77,533 4,672,702 126.69% 3.13% 1.31% 1,033,783 231.20 117.91 5.92 3.02 7.50 3.83 4.5200 2.31   -38.74%   40.05% 28-Jun-2013 5.24 2.27 88.51 1.16 1.13% 1.43% 21-Aug-2013 5.24 2.27 88.51 1.16 1.13% 1.43%
31-Dec-2013 22-May-2013 31-Mar-2013 1 2,531,100 174,900 134,100 99,900 77,562 4,684,751 77.64% 5.30% 2.13% 1,034,161 244.75 124.87 9.66 4.93 7.50 3.83 4.5300 2.31   -33.62%   -30.91% 29-Mar-2013 5.13 2.10 53.11 1.13 1.88% 1.46% 22-May-2013 5.39 2.20 55.80 1.19 1.79% 1.39%
31-Dec-2012 25-Feb-2013 31-Dec-2012 4 2,679,000 173,400 165,300 150,500 77,577 4,654,639 51.55% 6.17% 3.23% 1,034,364 259.00 132.17 14.55 7.42 7.50 3.83 4.5000 2.30   93.20%   -21.74% 31-Dec-2012 5.20 2.01 35.74 1.16 2.80% 1.44% 25-Feb-2013 4.70 1.81 32.30 1.04 3.10% 1.60%
31-Dec-2012 20-Nov-2012 30-Sep-2012 3 2,512,100 132,700 101,900 77,900 103,452 4,613,997 132.80% 4.06% 1.69% 1,034,528 242.83 123.93 7.53 3.84 10.00 5.10 4.4600 2.28   78.26%   -35.57% 28-Sep-2012 5.20 2.14 69.06 1.17 1.45% 1.92% 20-Nov-2012 4.99 2.05 66.27 1.12 1.51% 2.00%
31-Dec-2012 22-Aug-2012 30-Jun-2012 2 2,496,900 79,400 56,000 43,700 77,482 4,545,626 177.30% 2.24% 0.96% 1,033,096 241.69 123.18 4.23 2.16 7.50 3.82 4.4000 2.24   -69.78%   -76.40% 29-Jun-2012 5.32 2.20 125.77 1.21 0.80% 1.41% 22-Aug-2012 5.43 2.25 128.37 1.23 0.78% 1.38%
31-Dec-2012 28-May-2012 31-Mar-2012 1 2,358,000 222,900 188,700 144,600 77,575 4,582,102 53.65% 8.00% 3.16% 1,034,334 227.97 116.33 13.98 7.13 7.50 3.83 4.4300 2.26   -24.80%   28.88% 30-Mar-2012 5.43 2.38 38.84 1.23 2.57% 1.38% 28-May-2012 5.08 2.23 36.34 1.15 2.75% 1.48%
31-Dec-2011 27-Feb-2012 31-Dec-2011 4 2,554,300 245,100 230,100 192,300 93,098 4,892,840 48.41% 9.01% 3.93% 1,034,427 246.93 126.01 18.59 9.49 9.00 4.59 4.7300 2.41   59.06%   -7.95% 30-Dec-2011 5.25 2.13 28.24 1.11 3.54% 1.71% 27-Feb-2012 5.41 2.19 29.10 1.14 3.44% 1.66%
31-Dec-2011 21-Nov-2011 30-Sep-2011 3 2,188,700 167,100 144,300 120,900 206,827 4,352,776 171.07% 6.59% 2.78% 940,124 232.81 107.98 12.86 5.96 22.00 10.20 4.6300 2.15   -34.72%   31.56% 30-Sep-2011 4.49 1.93 34.91 0.97 2.86% 4.90% 21-Nov-2011 4.85 2.08 37.71 1.05 2.65% 4.54%
31-Dec-2011 18-Aug-2011 30-Jun-2011 2 2,225,300 250,600 223,000 185,200 - 4,343,268 - % 10.02% 4.26% 940,101 236.71 109.78 19.70 9.14 0.00 0.00 4.6200 2.14   65.06%   26.42% 30-Jun-2011 5.51 2.33 27.97 1.19 3.58% 0.00% 18-Aug-2011 4.90 2.07 24.87 1.06 4.02% 0.00%
31-Dec-2011 27-May-2011 31-Mar-2011 1 1,587,500 168,200 134,500 112,200 75,238 4,222,782 67.06% 8.47% 2.66% 940,486 168.80 78.32 11.93 5.54 8.00 3.71 4.4900 2.08   -46.29%   24.39% 31-Mar-2011 5.22 3.09 43.76 1.16 2.29% 1.53% 27-May-2011 5.10 3.02 42.75 1.14 2.34% 1.57%
31-Dec-2010 25-Feb-2011 31-Dec-2010 4 1,689,800 252,000 234,700 208,900 112,817 4,230,648 54.01% 13.89% 4.94% 940,144 179.74 83.36 22.22 10.31 12.00 5.57 4.5000 2.09   127.31%   41.44% 30-Dec-2010 4.79 2.66 21.56 1.06 4.64% 2.51% 25-Feb-2011 4.81 2.68 21.65 1.07 4.62% 2.49%
31-Dec-2010 29-Nov-2010 30-Sep-2010 3 1,513,900 153,700 124,600 91,900 112,876 4,091,760 122.82% 8.23% 2.25% 940,634 160.94 74.69 9.77 4.53 12.00 5.57 4.3500 2.02   -37.27%   6.61% 30-Sep-2010 4.38 2.72 44.83 1.01 2.23% 2.74% 29-Nov-2010 4.68 2.91 47.90 1.08 2.09% 2.56%
31-Dec-2010 23-Aug-2010 30-Jun-2010 2 1,425,000 185,900 161,400 146,500 93,431 4,054,910 63.78% 11.33% 3.61% 934,311 152.52 70.30 15.68 7.23 10.00 4.61 4.3400 2.00   62.42%   212.37% 30-Jun-2010 3.52 2.31 22.45 0.81 4.45% 2.84% 23-Aug-2010 3.88 2.54 24.74 0.89 4.04% 2.58%
31-Dec-2010 31-May-2010 31-Mar-2010 1 1,553,100 134,600 104,200 90,200 46,256 3,950,297 51.28% 6.71% 2.28% 925,128 167.88 76.62 9.75 4.45 5.00 2.28 4.2700 1.95   -38.93%   48.36% 31-Mar-2010 3.13 1.86 32.10 0.73 3.12% 1.60% 31-May-2010 3.15 1.88 32.31 0.74 3.10% 1.59%
31-Dec-2009 25-Feb-2010 31-Dec-2009 4 1,481,100 208,000 179,300 147,700 91,171 3,829,207 61.73% 12.11% 3.86% 911,716 162.45 73.07 16.20 7.29 10.00 4.50 4.2000 1.89   71.35%   33.56% 31-Dec-2009 3.08 1.90 19.01 0.73 5.26% 3.25% 25-Feb-2010 3.03 1.87 18.70 0.72 5.35% 3.30%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock for as low as 0.05% brokerage. Find out more.
  5 people like this.
 
EngCCCC Bstead today touch lowest price, 0.915. It seem as train to Batam.
08/01/2020 4:57 PM
Victor Yong Recent Prices
Date Open Range Close Change Volume
20/01/2020 0.935 0.93 - 0.94 0.93 -0.005 (0.53%) 208,700
17/01/2020 0.93 0.93 - 0.95 0.935 -0.005 (0.53%) 112,100
16/01/2020 0.945 0.935 - 0.945 0.94 -0.005 (0.53%) 276,500
15/01/2020 0.93 0.93 - 0.945 0.945 +0.015 (1.61%) 266,600
14/01/2020 0.94 0.925 - 0.94 0.93 -0.005 (0.53%) 454,100
13/01/2020 0.93 0.925 - 0.94 0.935 +0.005 (0.54%) 88,400
10/01/2020 0.92 0.92 - 0.93 0.93 +0.01 (1.09%) 442,100
09/01/2020 0.925 0.92 - 0.93 0.92 +0.005 (0.55%) 251,800
08/01/2020 0.93 0.915 - 0.935 0.915 -0.025 (2.66%) 766,400
07/01/2020 0.94 0.93 - 0.945 0.94 +0.005 (0.53%) 158,900
06/01/2020 0.96 0.935 - 0.96 0.935 -0.025 (2.60%) 561,000
03/01/2020 0.965 0.96 - 0.965 0.96 0.00 (0.00%) 1,016,900
02/01/2020 0.95 0.95 - 0.97 0.96 +0.01 (1.05%) 515,600
31/12/2019 0.975 0.95 - 0.98 0.95 -0.025 (2.56%) 410,400
30/12/2019 0.95 0.95 - 0.985 0.975 +0.03 (3.17%) 780,200
27/12/2019 0.93 0.93 - 0.96 0.945 +0.02 (2.16%) 306,600
26/12/2019 0.93 0.925 - 0.93 0.925 0.00 (0.00%) 228,600
24/12/2019 0.925 0.92 - 0.93 0.925 0.00 (0.00%) 221,800
21/01/2020 3:50 PM
Victor Yong Boustead: Associate delivers first mission vessel to royal navy. Boustead Heavy Industries Corporation Bhd’s (BHIC) associate company Boustead Naval Shipyard SB (BNS) has delivered to the Royal Malaysian Navy (RMN), the first of four littoral mission ships (LMS) it was commissioned to build. Defence Ministry undersecretary (Procurement Division) Datuk Ahmad Hussaini Abdul Rahman received LMS1, ‘KERIS’, witnessed by RMN Eastern Fleet commander Datuk Syed Zahrul Putra Syed Abdullah and BHIC chief executive officer Ir Ee Teck Chee. (The Edge)
21/01/2020 3:51 PM
Victor Yong BOUSTEAD Holdings Bhd is actively seeking a buyer for a 2.94-acre parcel in Jalan Cochrane, Kuala Lumpur, to unlock the value of the asset and enhance its cash flow.

The government-linked company had already put two valuable assets in Jalan Bukit Bintang up for sale — one last year and the other this year — and hopes to get at least RM147 million for the Cheras land, located a short walk from its MyTOWN shopping centre.

The Edge recently sighted an information memorandum on the sale.

When contacted, a Boustead spokesperson says, “We can confirm that on Nov 1, 2019, we sent a letter of invitation to selected registered real estate agents to identify interested buyers for the parcel of land located at the intersection of Jalan Cochrane and Jalan Shelley in Kuala Lumpur, opposite MyTOWN.

“The land is for sale on an ‘as-is’ basis, subject to restrictions in interest and conditions in the document of title at a minimum price of RM147 million before taxes, if any.”

The spokesperson adds that Boustead has been receiving numerous offers for the land since 2018. “However, the offers were deemed not attractive. In November 2019, the decision was made to actively seek a buyer.”

The sale is aligned with Boustead’s continuous drive to effectively manage its assets and extract the best value from its investments, according to the spokesperson. “The sale of this asset is expected to further enhance our cash flow and unlock value.”

The property division is involved in various aspects such as development, investment, project and property management, the spokesperson says. “This includes the buying and selling of assets, which is part and parcel of our principal activities and as a matter of course for our property business.

“Hence, the sale of this property (Jalan Cochrane) or any other property that we may have in mind to dispose of, is with a view to strengthen our portfolio and extract the best value from our investments.”

Citing the example of the Mutiara Damansara township in Selangor, the spokesperson says Boustead retained certain land parcels such as one The Curve sits on, even as it sold other plots to Tesco and IKEA. “As such, we have undertaken a similar strategy with our Cochrane township.”

The sale of property would enable Boustead to unlock its value via monetisation or in a joint venture with partners with strong financial resources and more defined expertise, the spokesperson says. Pooling resources would migitate risks, and, at the same time, provide a catalyst and variety to the developments it is involved in.

The Jalan Cochrane land is registered under Mutiara Rini Sdn Bhd, the shares of which are owned by Boustead Properties Bhd except for 1,000 shares held by Boustead, the parent of the latter. Mutiara Rini has held the land, designated for commercial use, since November 2012.

According to the information memorandum, the land has a freehold title with a plot ratio of four. At RM147 million, the price for the 127,865 sq ft parcel works out to RM1,150 per sq ft.

In the financial year ended Dec 31, 2018, Mutiara Rini registered a 16.5% decline in revenue to RM266.39 million. Net profit, however, improved 43.68% to RM139.79 million. Total liabilities stood at RM995.61 million, of which RM985.83 million are current, while retained earnings amounted to RM608.99 million.

Mutiara Rini also owns 50% of Boustead Ikano Sdn Bhd, and wholly owns Boustead Curve Sdn Bhd as well as Damansara Entertainment Centre Sdn Bhd.

As for Boustead, it incurred a loss of RM469 million on revenue of RM10.19 billion in FY2018 — its first net loss in 17 years.

As at Sept 30, total borrowings stood at RM8.19 billion with short-tem borrowings at RM4.55 billion. Cash balances and current receivables amounted to RM1.16 billion and RM1.42 billion respectively.

Earlier this month, The Edge reported that Boustead had invited bids for two adjacent parcels measuring 1.71 acres at the corner of Jalan Bukit Bintang and Jalan Pudu and set a collective reserve price of RM172 million. The offers received under the tender exercise, which closed in July, were ”not up to expectations” and the matter was put in abeyance. Nevertheless, the government-linked company continues to receive interest and as such, is evaluating its options although a decision has yet to be reached.

This parcel is located diagonally across from the Royale Chulan Bukit Bintang Hotel. Boustead inked a deal to sell the hotel in February last year to Singapore-listed Hotel Royal Ltd for RM197 million. The sale has yet to be completed.
21/01/2020 3:53 PM
Victor Yong Next month, Bplant should report profit, pharmaniaga also profit, BHIC also profit, Affin also profit, BHP Station also profit, Overall should report profit, dividend is back :) next month, result is out
21/01/2020 3:56 PM
Victor Yong BPlant is expected to contribute to Boustead in Q4, 2019 result to be released next month

1. GENERAL INTRO: BOUSTEAD PLANTATIONS is one of the main oil palm plantations in Malaysia.

2. NOTABLE POINTS:
a. In 2018 report, main business segments include operation of oil palm plantations and milling operations. In addition, the Group is also involved in the provision of mill design and consultancy services.
b. The Group operates 46 oil palm estates in Peninsular Malaysia, Sabah and Sarawak with a total planted area of 75,000 hectares and total annual fresh fruit bunches (FFB) production of 966,134 MT.
c. The group also operates 9 palm oil mill that has a capacity of 405 MT FFB per hour and produced 211,847 MT CPO in 2018. The reported average oil extraction rates (OER) is 21.2%, which is higher than MPOB's national average of 19.9%.
d. The Group also currently operates one biogas plant that captures methane gas produced from milling processes.
e. The Group posted a loss before tax of RM51 million for the financial year 2018. This was primarily as a result of significantly lower palm product prices which impacted its bottom line. High start-up expenses for the acquisition of 11,579 hectares of land in Sabah and the rehabilitation and improvements for these estates also contributed to the deficit.
f. As part of the Group’s efforts to reduce labour dependency, maximise effciency and optimise productivity, it continued with the mechanisation of its operations, including utilised harvesting tools such as lightweight graphite poles for tall palms, mini tractor grabbers with bin systems, motorised wheelbarrows (for hilly areas) and smart fertiliser spreaders.

3. IS THIS COUNTER A STRONG GROWTH STOCK?
a. REVENUE RANGE (RM million): 584 million as reported in 2018 annual report, this is a medium revenue company.
b. SHARE PRICE: from 2015-2018, share price has been steady at around RM1.50 , then on decreasing trend to around RM0.70 by around January 2020
c. EARNING PER SHARE (EPS): earning per share in last 5 years fluctuated from -2.3 to 27.7 sen
d. FUTURE POTENTIAL/PROSPECTS: share price expect to be stable in the next few years
e. CAPITAL EXPENDITURE (CAPEX): spending on purchase of new fixed assets is RM 82.6 million, around 2% of total assets.

4. IS THIS A STRONG DIVIDEND STOCK?
a. DIVIDEND YIELD: in 2018 financial year, BOUSTEAD PLANTATIONS declared a dividend payout of 7 sen per share to shareholders, which amounts to a dividend yield of 9.72%.
b. CONSISTENCY: the dividend payout was consistent, dividend paid to shareholders in last five years (2014-2018) ranged from 6 to 19.5 sen per share, with a dividend yield range from 4.1 to 11.8 %.
c. DIVIDEND PAYOUT RATIO: N/A

5. IS THE MANAGEMENT PERFORMANCE GOOD?
a. RETURN ON EQUITY (ROE): in 2018 financial year, BOUSTEAD PLANTATIONS achieved a low return of shareholders’ equity, at -1.8%. Last five years ROE ranged from -1.8 to 21.7%.
b. COST-TO-INCOME RATIO: N/A

6. OTHER INDICATORS:
a. CASH FLOW: cash flow is positive, around RM 52.6 million, equivalent to RM 0.02 per share
b. SUPPORT BY INSTITUTIONAL INVESTORS: this counter is well supported by institutional investors, there are 18 institutional investors at top 30 major shareholders list, including EPF (4.76%), insurance companies and investment funds. Its major shareholders are Boustead Holdings Berhad (57.42%) and Lembaga Tabung Angkatan Tentera (12.1%).

Disclaimer: The content of the blog posts are for sharing purpose only. Readers are encouraged to carry out further research and analysis as well as follow up latest update information before making any investment decisions.
21/01/2020 4:08 PM
Victor Yong BHIC will also start to contribute profit to Boustead


1. GENERAL INTRO: This counter core business is on ship building and repair for defense industry.

2. NOTABLE POINTS:
a. business segments include commercial and naval ship building and repair, clientele include Royal Malaysia Navy, local and overseas ship owners, also fabrications works for oil &gas industry. Also involve manufacturing of aerospace components and propellents.

3. IS THIS COUNTER A STRONG GROWTH STOCK?
a. REVENUE RANGE (million): ~ 277.6 million in 2017 annual report, this is a low revenue company.
b. SHARE PRICE: share price on decreasing trend in last few years, decreased from peak of RM3.80 in 2012 to current share price of RM1.30.
c. EARNING PER SHARE (EPS): earning per share in last 5 years are fluctuating, from -12.37 to 30.87 sen per share, making losses in one out of five years
d. FUTURE POTENTIAL/PROSPECTS: for ship building and maintenance segment, expect steady revenue from defense department contracts, while business segment related to oil&gas industry remaining challenging due to slower demand for hydrocarbon energy from developing economies as well as the shift towards renewable energy.
e. CAPITAL EXPENDITURE (CAPEX): spending on purchase of new fixed assets is 2 million, around 0.3% of total assets.

4. IS THIS A STRONG DIVIDEND STOCK?
a. DIVIDEND YIELD: in 2017 report, dividend of 5sen per share payout declared, amount to dividend yield of 3.85%
b. CONSISTENCY: in last five years only in 2017 there was dividend payout to shareholders, no dividend declared from 2013-2016

5. OTHER INDICATORS:
a. CASH FLOW: cash flow is positive, around 45.8 million
b. SUPPORT BY INSTITUTIONAL INVESTORS: there is presence of 2 institutional investors at top 30 major shareholders list, which are Lembaga Tabung Haji and Lembaga Tabung Angkatan Tentera.

Disclaimer: The content of the blog posts are for sharing purpose only. Readers are encouraged to carry out further research and analysis as well as follow up latest update information before making any investment decisions.
21/01/2020 4:10 PM
Good123 above rm1 again after q4,2019 result is released next month :)
21/01/2020 4:16 PM
Good123 what if dividend is declared together with the results next month。 LTAT needs money for army retirement
21/01/2020 4:17 PM
Good123 all conglomerate GLCs had recovered substantially in share price, but boustead has been overlooked :)
21/01/2020 4:20 PM
Good123 pharmaniaga, bic, affin, pharma, Bhp stations will report profit next month. takda impairment lagi
21/01/2020 4:21 PM
Good123 affin will apply for digital bank license if not mistaken
21/01/2020 4:21 PM
Good123 next assets per share rm2.59
21/01/2020 4:22 PM
Good123 the cheapest GLC based on.Price/book value
21/01/2020 4:23 PM
Good123 probably the cheapest p/b glc stock
21/01/2020 4:23 PM
Victor Yong reversal of impairment probably :) Q4,2019 results next month will be interesting

Monday, December 2nd, 2019 at , Markets | News



The firm had provided impairments over RM160m for its heavy industries and property divisions

by FARA AISYAH / pic by TMR

BOUSTEAD Holdings Bhd slipped into the red as impairments totalling RM161.3 million dragged the conglomerate into a RM155 million net loss for the third quarter ended Sept 30, 2019 (3Q19).

The company had provided impairments over RM160 million for its heavy industries and property divisions.

During the same quarter last year, the group, almost 60%-owned by Lembaga Tabung Angkatan Tentera (LTAT), registered a RM7.3 million net profit. It also posted a loss per share of 7.65 sen in the three months, compared to earnings per share of 0.36 sen in 3Q18.

Boustead’s quarterly revenue, however, increased 5% year-on-year (YoY) to RM2.73 billion from RM2.6 billion in 3Q18.

For the nine-month period (9M19), Boustead’s net loss widened to RM153.1 million from RM14.2 million last year. Besides impairments, the group incurred higher finance cost and operating losses recorded by its plantation and heavy industries divisions.

The group’s revenue in 9M19 increased 6.28% YoY to RM7.79 billion from RM7.33 billion in the same period last year due to higher contributions from most of its business segments.

“Despite headwinds, the group recorded solid revenue growth for the 9M19,” Boustead MD Datuk Seri Amrin Awaluddin (picture) said in a statement last week.

“However, due to the one-off impairments in the property and heavy industries divisions, our bottom line was impacted,” he added.



Revenues from the pharmaceutical division in January to September 2019 improved to RM2.1 billion from RM1.8 billion in 9M18 due to solid contributions from both the concession and non-concession businesses.

The property division’s revenue increased by 9% to RM400.5 million in 9M19, largely due to higher progress of works for development activity at Taman Mutiara Rini, Johor, and One Cochrane Residences, Kuala Lumpur.

Boustead’s finance and investment division also posted higher revenue of RM154.5 million in 9M19, reflecting a 5% increase, mainly due to higher tuition fees from the University of Nottingham Malaysia Campus.

However, the trading and industrial, as well as plantation divisions registered lower revenues of RM3.8 billion (RM4 billion in 9M18) and RM398.1 million (RM427.4 million in 9M18) respectively, mainly due to lower commodities prices.

“As we strive to achieve a turnaround for the group, we are cognisant of the challenges we face in the current operating environment.

“We remain focused on enhancing efficiencies and extracting further value within the respective operating units, with a view to deliver sustainable earnings over the long term,” Amrin said.

Meanwhile, Boustead Plantations Bhd has appointed a new CEO Ibrahim Abdul Majid effective Dec 1, 2019.

Boustead Plantations also announced the promotion of Mohamad Mahazir Mustaffa as its new CFO and the appointment of Noral Afida Alwi as its new financial controller.

Boustead closed one sen or 0.52% higher to 97 sen last week, giving it a RM1.96 billion market capitalisation.
21/01/2020 4:28 PM
Victor Yong Nature of Interest Direct Interest
Shares Ordinary shares of RM0.50 each.
Reason LTAT - Acquisition 113,000 shares. Citigroup Nominees - Transferred 113,000 shares. MAM - Disposal 200,000 shares.
Total no of securities after change
Direct (units) 1,204,752,018
Direct (%) 59.44
Indirect (units) 0
Indirect (%) 0.00
Total (units) 1,204,752,018
Total (%) 59.44
Date of Notice 13-Jan-2020
21/01/2020 4:31 PM
Victor Yong Nature of Interest Direct Interest
Shares Ordinary shares RM0.50 each.
Reason Citigroup Nominees (Tempatan) Sdn Bhd Employees Provident Fund Board ("EPF") - Disposal of 400,800 shares.
Total no of securities after change
Direct (units) 101,097,148
Direct (%) 4.99
Indirect (units) 0
Indirect (%) 0.00
Total (units) 101,097,148
Total (%) 4.99
Date of Notice 09-Jan-2020
21/01/2020 4:32 PM
Victor Yong If sars returns, good biz for pharma supplying vaccine to hospitals, etc :)
21/01/2020 5:01 PM
Victor Yong Bplant will contribute profit to boustead this year :)

KUALA LUMPUR (Jan 21): Average palm oil prices will surge 17.9% this year, a Reuters poll of industry participants showed, as reduced output in the first half of the year and higher biodiesel consumption in top producers Indonesia and Malaysia tighten the market.

Benchmark palm oil prices will average RM2,650 (US$650.80) a tonne in 2020, up from RM2,248 last year, according to the median estimate from a poll of 18 analysts and industry players.

"With relatively low production in the first quarter, production will only be sufficient for export and not for topping up stock," said Derom Bangun, chairman of the Indonesia Palm Oil Board.

Supplies are expected to rebound later in the year, however, and prices could be "much lower from April to December", said Sandeep Bajoria, chief executive of Sunvin Group, a vegetable oil importer based in Mumbai.

Indonesia's palm production is pegged to rise 0.55% to 45.75 million tonnes in 2020 from an estimated 45.5 million tonnes in 2019, according to the median estimate of 14 poll respondents who answered questions specifically on Indonesia's palm sector.

This is compared to output growth of 5.8% in 2019 over 2018's total of 43 million tonnes, sources said.

Output in No.2 producer Malaysia will grow by 0.35% to 19.93 million tonnes this year, based on the median estimate from 14 participants.

In 2019, Malaysia's production rose 1.85% to 19.86 million tonnes, up from 2018's 19.5 million tonnes.

The slower output growth is due to dry weather and lower fertiliser usage in both countries last year, when palm prices dropped as low as RM1,960.

Indonesia and Malaysia together account for nearly 90% of global palm production.

BIODIESEL

"(In) year 2020 much depends on whether Indonesia can produce 10 million kilolitres of biodiesel," said Christopher Chai, a general manager with Malaysia's Kwantas Corp.

The market will be closely watching the roll-out of Indonesia's B30 biodiesel programme — biodiesel with 30% palm content — and Malaysia's newly implemented B20 programme, as together they are expected to increase local consumption by 10%-13%, traders said.

Indonesia is targeting 10 million kilolitres (8.7 million tonnes) of biodiesel production this year, while Malaysia's biodiesel association is expecting to produce 1.7 million to 2 million tonnes of the fuel.

TRADE WARS

Ongoing trade disputes between China and the United States, India and Malaysia, and the European Union and Indonesia will likely affect export shipments this year, poll respondents said.

"The Indonesian government's battle with the EU on the latter imposing anti-dumping duties on Indonesian biodiesel exporters will hog the media attention," Sathia Varqa, owner and co-founder of Singapore-based Palm Oil Analytics, said.

Malaysia benefited from the trade war between the United States and China in 2019, with exports to China rising by 33.9% last year. However, a trade deal between the two largest economies may see China resume purchases of US soybeans, which may result in a lower demand for palm oil.

India, the world's largest edible oil buyer, as well restricted overall imports of refined palm oil on Jan 8, and informally instructed its traders to avoid purchases from Malaysia following a diplomatic squabble.

(US$1 = RM4.0720)
21/01/2020 5:33 PM
Victor Yong Boustead should be next for healing after fgv :)

LAST Thursday, shares of Boustead Heavy Industries Corp Bhd (BHIC) closed at RM1.26.

The stock has remained below the RM1.40 threshold — lows unseen for at least five years — for about 11 months.

Its last peak in the past 18 months was on Jan 19 last year when the stock hit RM2.11. By July 6, it had shed 36.5% of its market value to RM1.34 and has not recovered to date.

Interestingly, even though BHIC has announced a number of new contracts since late 2018, its share price has not budged, sparking suspicion among some shareholders that it is being deliberately suppressed by an unknown party.

“BHIC’s share price is a function of market sentiments, hence we cannot comment on the matter,” BHIC says when asked what it is doing to address these concerns. “We continue to focus on maximising shareholder value ... we trust that discerning shareholders will appreciate the long-term value proposition.”

For the Armed Forces Fund Board (LTAT) and its 59.45%-owned listed vehicle, Boustead Holdings Bhd, BHIC’s lacklustre share price performance puts them at a crossroads.

LTAT is the ultimate controlling shareholder of BHIC with a direct stake of 8.16% while Boustead Holdings controls another 65%.

LTAT is looking to rebalance its investment portfolio, which is significantly concentrated in chunky equity investments on Bursa Malaysia.

About 60% of LTAT’s RM10 billion fund is in listed equities — primarily in the Boustead group of companies, which includes BHIC.

LTAT CEO Nik Amlizan Mohamed, who was appointed last September, told The Edge at the time that rebalancing LTAT’s portfolio is the long-term agenda, although she stressed that LTAT is “patient capital” and will not rush the process.

In a statement to The Edge, LTAT says it periodically reviews its investments, including those in BHIC, in keeping with its aim to generate sustainable returns for its members.

“Nevertheless, at this juncture in time, there are no concrete plans to divest LTAT’s stake in BHIC,” the fund adds.

LTAT did not address queries on whether it would be open to paring down its stake, either partially or wholly, or whether it has been approached by interested investors in a possible sale.

In any event, BHIC may require special consideration among the various businesses in the Boustead group as far as portfolio rebalancing goes.

In the short term, LTAT’s direct and indirect shareholding in BHIC, amounting to 73.16%, means liquidity could also be shackling its value.

As the shipbuilder’s recent financial performance has also hurt returns for LTAT, it makes sense for the fund to gradually reduce its stake and redeploy its capital.

However, the current low valuation means any divestment will likely mean its books will take a hit. LTAT did not respond to queries on its holding cost for the BHIC shares.

Another factor could be what moves Boustead Holdings, which welcomed new managing director Datuk Seri Amrin Awaluddin on May 6, makes down the road.

Setting a new direction for Boustead Holdings will undoubtedly include deciding what to do with its sprawling interests, including its 65% stake in BHIC. It is worth noting that Amrin also joined Minister of Defence Mohamad Sabu’s visit to BHIC’s shipyard in Lumut last month.

Counter-balancing these considerations, however, is the fact that BHIC is unique as it is effectively a monopoly military shipbuilder for the government.

While other major businesses in the Boustead group such as plantations, banking, property and pharmaceuticals have industry peers that LTAT can invest in to spread the risk, BHIC cannot be replaced like-for-like in LTAT’s portfolio.

Also, the pipeline of contracts coming from the Royal Malaysian Navy over the next decade plus possible military spending boosts from the upcoming Defence White Paper paints a picture of BHIC soon being on the cusp of a boom wave.

LTAT and Boustead Holdings will thus have to decide on its priorities as far as BHIC is concerned.
21/01/2020 6:15 PM
Victor Yong Time to help the army. :)

About 60% of LTAT’s RM10 billion fund is in listed equities — primarily in the Boustead group of companies, which includes BHIC.
21/01/2020 6:16 PM
Good123 bulan depan akan tahu sama ada kamu tipu :)

PETALING JAYA: Boustead Holdings Bhd expects to return to profitability in current financial year ending Dec 31 (FY19).
The group plunged into the red with a net loss of RM469.2 million in FY18 in light of the losses incurred by its heavy industries and plantation divisions, while other divisions registered moderate earnings as a result of trying economic conditions.
Executive director Datuk Seri Ghazali Mohd Ali said “the ingredients for success are there” and it is a matter of discussing and strategising it before year-end.
“Our assets are there, our plans are there, manpower is there. Those three ingredients alone will bring success and a fresh outlook for the new group managing director (MD) will help the organisation in achieving its targets,” he told a press conference after the group’s AGM today.
He declined to reveal the “plans”, citing pending discussions with the new MD Datuk Seri Amrin Awaluddin, who will begin his new role on May 6.
“We’ll be discussing with him (Amrin) and the board before we go ahead and implement. Rest assured that the management and the board is working at turning the company around from the results of this year,” said Ghazali.
He commended Amrin for his experience and track record, especially in property development, as well as his strong finance background, adding that the group has the framework ready for somebody to take over and lead the group forward.
He emphasised that Boustead is asset-rich and from the perspective of businesses, the group is in a strong position with clear prospects ahead.
“We firmly believe that as long as we remain persistent in strengthening the foundation of our businesses, and tapping opportunities for growth, we will see results in the medium to long term future. What got us here will not get us there. We have to reinvent ourselves in certain areas, we have to look at ourselves and work at our strengths,” said Ghazali.
Meanwhile, he said there will be one or two more asset disposals this year to pare down its borrowings. Its gearing ratio stands at 0.9 times, which is deemed comfortable for the group.
On the disposal of its Royale Chulan Bukit Bintang Hotel, he said the government (Economic Planning Unit) is doing the valuation for the hotel and the group expects to obtain the outcome in a month.
Earlier at the AGM, three resolutions were not passed by the shareholders, including the re-election of Datuk Wira Dr Megat Abdul Rahman Megat Ahmad as director, retention of chairman Gen Tan Sri Panglima Mohd Ghazali Che Mat (R) as independent director and the retention of Abdul Rahman as independent director.
21/01/2020 6:54 PM
Good123 What is the thing happen with Boustead and how do we capture the oppurtunity
https://klse.i3investor.com/blogs/SICStockPick/225376.jsp
21/01/2020 7:05 PM
Good123 Should You Invest In Boustead Holding? https://klse.i3investor.com/blogs/TenNinetyCapital/224691.jsp
21/01/2020 7:07 PM
Good123 [转贴] [BOUSTEAD HOLDINGS BHD:由于特许经营和非特许经营业务的销售额都增加,制药事业部取得了更高的收入;由于造船和修船活动取得了进展,来自重工业部门的收入也更高] - James的股票投资James Share Investing https://klse.i3investor.com/blogs/general/229239.jsp
21/01/2020 7:10 PM
Victor Yong Continuous improvement for boustead group of companies, good :)

KUALA LUMPUR (Jan 21): Pharmaniaga Bhd, the country's largest pharmaceutical company, is slated to announce the departure of its managing director (MD) Datuk Farshila Emran (pictured) after nine years at the helm.

A person with knowledge of the matter told theedgemarkets.com that the board of directors will not be extending Farshila's contract when her current contract expires in April. Farshila, 52, was appointed to the board of directors of Pharmaniaga on March 25, 2011, prior to becoming its MD on April 1, 2011.

It is understood that Mohamed Iqbal Abdul Rahman, the current chief operating officer of Pharmaniaga, will assume the role of acting MD following Farshila's departure.

As at Feb 28, 2019, Pharmaniaga is 67.32% owned by Lembaga Tabung Angkatan Tentera, of which 56.09% is held through Boustead Holdings Bhd.

According to Pharmaniaga's Annual Report 2018, Farshila founded Idaman Pharma Sdn Bhd (IPSB) in 2001 and started her venture in the highly regulated pharmaceutical industry. Under her leadership, IPSB developed a synergistic partnership with Boustead and facilitated the acquisition of Pharmaniaga by Boustead in 2011.

Since December 2018, Pharmaniaga has seen several changes to its board.

On Dec 31, 2018, Pharmaniaga announced the resignation of its chairman Tan Sri Che Lodin Wok Kamaruddin, 69, citing early mutual termination of his service agreement with Boustead as MD on the same day.

Subsequently, it saw four other board resignations, namely Tan Sri Dr Mohamed Ismail Merican, 71, Fahmy Ismail, 42, Ebinesan @ Daniel Gnanakkan, 73, and Izzat Othman, 57.

On July 17 last year, Datuk Dr Hafsah Hashim, 61, was appointed as independent and non-executive chairman of Pharmaniaga. Hafsah has served the government for 36 years before retiring on Aug 15, 2018, during which she held several senior positions, including chief executive officer of SME Corp Malaysia.

Other new appointments to the board included Datuk Koo Hock Fee, 68, Datuk Mohd Zahir Zahur Hussain, 44, and Brig Gen (R) Datuk Mohd Shahrom Mohamad, 66, as directors.

More recently, on Dec 24, 2019, Pharmaniaga announced the appointment of Dr Salmah Bahri, 61, as its independent and non-executive director effective Jan 1. She was the senior director of pharmaceutical services at the Health Ministry from Nov 1, 2016 to July 18, 2018.

On Nov 18, 2019, Pharmaniaga's wholly-owned subsidiary, Pharmaniaga Logistics Sdn Bhd (PLSB), received a letter from the Health Ministry for an extension of its services for the provision of medicines and medical supplies to the ministry's facilities for an interim period of 25 months, from Dec 1, 2019, to Dec 31, 2021.

In addition, PLSB secured a five-year contract to continue providing logistics and distribution services for the Health Ministry for five years ending Dec 31, 2024.

Pharmaniaga shares closed up 2 sen or 0.97% at RM2.09 today, bringing it a market capitalisation of RM545.97 million.
21/01/2020 7:32 PM
Victor Yong Boustead has stake in affinbank :)

Last year, technology firm Grab, telco Axiata Group Bhd (which owns e-wallet “Boost”) and at least five banks — CIMB Group Holdings Bhd, Affin Bank Bhd, Hong Leong Bank Bhd, AMMB Holdings Bhd and Standard Chartered Bank Malaysia Bhd — had signalled their interest in pursuing a digital banking licence in Malaysia.
21/01/2020 8:38 PM
Victor Yong Bhic will report profit too

KUALA LUMPUR (Jan 2): Boustead Heavy Industries Corporation Bhd’s (BHIC) associate company Boustead Naval Shipyard Sdn Bhd (BNS) has delivered to the Royal Malaysian Navy (RMN), the first of four littoral mission ships (LMS) it was commissioned to build.

Defence Ministry undersecretary (Procurement Division) Datuk Ahmad Hussaini Abdul Rahman received LMS1, ‘KERIS’, witnessed by RMN Eastern Fleet commander Datuk Syed Zahrul Putra Syed Abdullah and BHIC chief executive officer Ir Ee Teck Chee.

BNS signed a procurement contract with the government on March 23, 2017 to build four LMS in partnership with China Shipbuilding and Offshore International Corporation Ltd in China.

In a statement, the group said the LMS is capable of operating in multi-mission roles and in all weather conditions.

With a length of 68 metres and a maximum speed of 22 knots, the LMS has a complement of 45 crew members plus 16 personnel on detachments, and an endurance of 15 days at sea, it said.

Meanwhile, BHIC non-executive chairman, admiral (rtd) Tan Sri Ramlan Mohamed Ali said the close collaboration between BNS and RMN’s LMS project teams and the skills and capabilities of the personnel had contributed to the timely delivery of KERIS and smooth progress of the project.

“All milestones of KERIS, leading to its handover, have been met according to schedule, from the First Steel Cut on July 31, 2018 to its Keel-Laying on Oct 23, 2018 and to its launching on April 15, 2019,” he added.
21/01/2020 9:37 PM
Victor Yong After restructuring felda's fgv, now LTAT's boustead turn probably :)

Universiti Malaya’s Faculty of Economics and Administration Prof Edmund Terence Gomez criticised Pakatan Harapan’s first economic policy – the Shared Prosperity Vision (SPV) 2030 – labelling it as a continuation of the previous New Economic Policy (NEP) 1970-1990.

He said the 10-year economic policy was race-based in nature, although the ruling coalition had clearly stated in its manifesto the necessity to introduce need-based policies.

Gomez added that SPV continued to rely on the bumiputra-non-bumiputra dichotomy, similar to NEP.

“Not only that, the SPV did not mention the government-linked companies (GLCs) and the urgent need for reform GLCs. Only the small and medium enterprises were discussed.
22/01/2020 8:10 AM
Victor Yong Boustead will rebound a lot next month after Q4, 2019 result is released.

BHP petrol stations - Up
Pharmaniaga - Up
BPlant - Up (CPO price has risen like crazy)
Affin Bank - Up
BHIC - Up
Gain on disposal, etc
22/01/2020 8:48 AM
Victor Yong Boustead's cash cow :)

BHPETROL
RELIABLE. FRIENDLY. PROGRESSIVE.
Boustead Petroleum Marketing Sdn Bhd is a member of the Boustead Group of Companies. Since the launch of BHPetrol in 2005, its unwavering efforts to market and distribute top notch petroleum products have seen the company’s steady expansion across Malaysia. Today, it retails fuel via a network of over 400 service stations under BHPetrol, and market Liquefied Petroleum Gas (LPG) and lubricants product.


DRIVEN BY PASSION TO BRING YOU THE BEST FUEL
Continue striving to provide ever better products and services that allow us to connect and keep connecting with you in new ways that add value to your drive and positive experiences with BHPetrol.

Whether you are an individual, commercial, or industrial customer, you experience every value-added advantage of BHPetrol’s 3 Brand Values:
Consistently RELIABLE products and services
Sincerely FRIENDLY services
Ever PROGRESSIVE technology
Today, we’ve come a long way to greatly advance the marketing and distribution of petroleum products. We retail top-notch fuels via a network of over 400 BHPetrol service stations, efficiently market Syngard Liquefied Petroleum Gas (LPG) and lubricants, and operate over 290 shops within our network of service stations to ensure our customers experience greatly added value above comfort and convenience whenever you drive by.

Our commitment to provide only the best to customers led us to develop Infiniti, the revolutionary fuel incorporating a proprietary additives’ package that not only enhances an engine’s performance and responsiveness, but also provides more mileage.

BHPetrol is committed to bring you the best quality fuels simply because we are passionate about ensuring that Malaysian motorists enjoy the best performance and mileage out of your cars.

​To date, we have over 290 convenience store within our retail service station network, all of which offers a wide range of quality products at top value to ensure customers enjoy a consistently positive impact, as you gain more points you can instantly redeem for an impressive variety of exclusive items from favorite brands.
22/01/2020 8:51 AM
Victor Yong Boustead's cash cow :)

BHPETROL - Product range


STATION
Station
Station Locator
Safety at the Station

FUEL
Infiniti RON95 Euro4M & RON97 Euro4M
Infiniti Euro2 & Euro5 Diesel

MART
BHPetromart
Other Services
Promotions
Other Offerings

CARDS & SERVICES
(NEW!) eCard Mobile App
eCard Loyalty Program
X-Fleet Card
AFFINBANK BHPetrol Card
SmartDrive Motor Insurance

LUBES
BHPetrol Lubricants
SynGard
Trans
Dash
Others

LPG
BHPetrogas
Domestic & Commercial Cylinders
Switch to BHPetrogas LPG
Safety at Home
Storage & Distribution
22/01/2020 8:53 AM
Victor Yong BPlant will report profit again in Q4, 2019 due to high CPO price :) It would help to boost Boustead's overall profitability. Hopefully, Boustead will declare dividend next month when Q4, 2019 result is released.

Aug 23, 2019

Boustead Plantations back in the black in Q2

Aug 23, 201 9
Disposal gain lifts Boustead Plantations back to profitablity

Aug 23, 2019
Boustead Plantations back in the black
22/01/2020 8:56 AM
Victor Yong Turnaround of BPlant will surely boost Boustead's overall profitability. :)

Boustead Plantations Berhad ("BPB") is one of the most experienced and established upstream oil palm plantation company in Malaysia and a subsidiary of Boustead Holdings Berhad ("BHB"), one of Malaysia's oldest and largest diversified conglomerates. Backed by BHB's presence in the plantations business, we have over 100 years of plantations industry experience and over 50 years of oil palm plantation estate management experience.

We are an investment holding company and are involved in the ownership of oil palm plantations. Through our subsidiaries, we are principally involved in the ownership and management of oil palm plantations, cultivation of oil palm and harvesting of its Fresh Fruit Bunches ("FFBs"), and the production and sale of Crude Palm Oil ("CPO") and Palm Kernel ("PK"). We also sell oil palm FFBs and provide mill design and consultancy services. We are also actively involved in oil palm agricultural and agronomic research through our associate company.

We own, co-own or lease a total of 41 oil palm plantation estates and 10 palm oil mills in Malaysia with 19 plantation estates in Peninsular Malaysia, 13 in Sabah and 9 in Sarawak. We own and operate 4 palm oil mills in Peninsular Malaysia, 4 in Sabah and 2 in Sarawak. Our total landbank stands approximately at 82,500 Ha. Out of this total, the area under oil palm cultivation is around 64,500 Ha comprising of 24,900 Ha in Peninsular Malaysia, 27,200 Ha in Sabah and 12,400 Ha in Sarawak.

Our involvement in the plantations business is carried out via our wholly-owned subsidiary, Boustead Estates Agency Sdn Bhd ("BEA"), a central agency which provides a range of services such as the management of all plantation activities within our Group, plantation advisory services for oil palm and rubber crops, plantation engineering services, marketing of plantation produce and agronomic research.

“Whereas our involvement in the oil palm agricultural and agronomic research is through our associate company, Applied Agricultural Resources Sdn Bhd ("AAR"). AAR provides agronomic advisory services and commercial production of oil palm planting materials namely AA Hybrida IS, oil palm hybrid semi-clonal seeds, is produced through a pedigree of selected elite clonal Deli Dura and the Dumpy Yangambi AVROS pisifera. This pisifera is the combination of the highly successful and renowned dumpy characteristic of AAR’s previous hybrid (the Dumpy AVROS) with the high bunch number characteristics of the Yangambi AVROS. The end result is an oil palm variety with 22% more oil yield compared to AAR’s previous AA DxP planting materials. For more information on AA Hybrida IS, please visit AAR website.

AAR-UNMC Biotechnology Research Centre, is a collaboration between AAR and the University of Nottingham Malaysia Campus. This has resulted in a new state-of-the-art biotechnology research centre which is primarily involved in the development of oil palm, with a focus in genetic improvement through modern bio molecular marker techniques. The research areas being explored include the application of Deoxyribonucleic Acid (DNA) finger printing and genetic improvement programmes.overview

The main goals of the research centre are to develop genetic engineering technology to overcome the barriers of introducing new traits into oil palm and speed up the production of new oil palm hybrid with desirable traits, such as high value oil, disease resistance and amenability to mechanise harvesting using marker assisted selection and tissue culture.

The Group's commitment in pursuing sustainable practices is on-going. As of to date the Roundtable on Sustainable Palm Oil certification has been obtained for Sungai Jernih Business Unit and Nak Business Unit which consist of one (1) mill and three (3) estates respectively.
22/01/2020 8:58 AM
Victor Yong Q4,2019 results next month will be interesting :) (Jan 21): Average palm oil prices has surged 17.9% this year

takda lagi impairments totalling RM161.3 million.

Friday, 29 Nov 2019

5:08PM BSTEAD Nine-month net loss 92.000 million
22/01/2020 9:04 AM
Victor Yong with the virus like H1N1 emerged again, pharmaniaga's share price surged this morning. Expecting more sales for pharmaniaga as hospitals, etc will buy more vaccines, etc , also another company where Boustead has substantial stake. :)

As Malaysia’s largest listed integrated pharmaceutical group, Pharmaniaga Berhad has blazed a trail within the healthcare industry as a provider of quality products and services. Listed on the Main Board of Bursa Malaysia and having established itself as a leader in the local market, Pharmaniaga also has a growing global presence.

As part of our drive to become a total integrated healthcare solutions provider, our core businesses span across a wide spectrum of the industry. This includes logistics and distribution, manufacturing of generic pharmaceuticals, sales and marketing, as well as distribution of medical products and hospital equipment. Drawing upon the synergies of these activities, Pharmaniaga has expanded its reach to Malaysians through the establishment of community pharmacy.

The heart of our corporate philosophy is driven by our motto, Passion for Patients. Above all, we emphasise on delivering our promises to our clients with the highest standards of excellence, as we seek to create a lasting legacy of doing business with a conscience.

Vision
The preferred pharmaceutical brand in regional markets.

Mission
Provide quality products and superior services by professional, committed and caring employees.
22/01/2020 9:18 AM
Good123 time to grab some . :)
22/01/2020 9:25 AM
Good123 next month, probably report overall profitability for 2019 and declare dividend, share price will exceed rm1
22/01/2020 9:26 AM
Good123 based on P/B, cheapest conglomerate GLC :)
22/01/2020 9:27 AM
Good123 LTAT needs money to fund army retirement, this year, boustead will pay dividend again
22/01/2020 9:28 AM
Victor Yong :)

52 Weeks Range: 0.915 - 1.60
22/01/2020 9:51 AM
Victor Yong KUALA LUMPUR: Pharmaniaga Bhd managing director (MD) Datuk Farshila Emran (pic) will leave the company when her contract expires at end-March this year, the country’s largest pharmaceutical company announced.

This confirmed a report by theedgemarkets.com yesterday, citing a person with knowledge of the matter, that Pharmaniaga will not be extending Farshila’s contract when it expires.

In a filing with Bursa Malaysia yesterday, Pharmaniaga said Farshila, 54, is leaving “on completion of service contract” after nine years with the company. She joined Pharmaniaga’s board on March 25, 2011, before becoming its MD on April 1 the same year.

In a separate statement, Pharmaniaga said Farshila is currently pursuing her PhD.

It also confirmed that Mohamed Iqbal Abdul Rahman, currently serving as chief operating officer, will become acting MD following Farshila’s departure.

“Mohamed Iqbal will assume the role of acting MD of Pharmaniaga until such a time a MD of Pharmaniaga is appointed. Pharmaniaga assures that it will be business as usual and there will be a seamless transition across its groups of companies until a [new] MD is appointed,” it said.

As at Feb 28, 2019, Pharmaniaga is 67.32% owned by Lembaga Tabung Angkatan Tentera, of which 56.09% is held via Boustead Holdings Bhd.

According to Pharmaniaga’s Annual Report 2018, Farshila founded Idaman Pharma Sdn Bhd (IPSB) in 2001 and started her venture in the highly regulated pharmaceutical industry. Under her leadership, IPSB developed a synergistic partnership with Boustead and facilitated the acquisition of Pharmaniaga by Boustead in 2011.

Since end-2018, Pharmaniaga has seen several changes to its board, starting with the resignation of its chairman Tan Sri Che Lodin Wok Kamaruddin, 69, which Pharmaniaga announced on Dec 31 that year, citing a mutual early termination of his service agreement with Boustead as MD.

Subsequently, it saw four other board resignations, namely Tan Sri Dr Mohamed Ismail Merican, 71; Fahmy Ismail, 42; Ebinesan @ Daniel Gnanakkan, 73; and Izzat Othman, 57.

On July 17 last year, Datuk Dr Hafsah Hashim, 61, was appointed as independent and non-executive chairman of Pharmaniaga. Hafsah served the government for 36 years — during which she held senior positions like the chief executive officer (CEO) of SME Corp Malaysia — before retiring on Aug 15, 2018.

Other new appointments to the board included Datuk Koo Hock Fee, 68; Datuk Mohd Zahir Zahur Hussain, 44; and Brig Gen (R) Datuk Mohd Shahrom Mohamad, 66, as directors.

On Dec 24, 2019, Pharmaniaga announced the appointment of Dr Salmah Bahri, 61, as its independent and non-executive director effective Jan 1. She was the senior director of pharmaceutical services at the health ministry from Nov 1, 2016 to July 18, 2018.

The change of leadership at Pharmaniaga follows other key resignations related to government-linked companies and state-owned firms in recent times, including that of Keretapi Tanah Melayu Bhd CEO Mohd Rani Hisham Samsudin, Prasarana Malaysia Bhd CEO Mohamed Hazlan Mohamed Hussain and Malaysia Airports Holdings Bhd group CEO Raja Azmi Raja Nazuddin.

Shares in Pharmaniaga have fallen 25.6% over the past 12 months to close at RM2.09 yesterday, bringing it a market capitalisation of RM545.97 million.

The share price decline is partly due to news that Pharmaniaga’s concession to distribute drugs and medical supplies for the health ministry will end come Dec 31, 2021.

Nevertheless, it has managed to secure a five-year contract to continue providing logistics and distribution services to the health ministry for five years ending Dec 31, 2024.

For the cumulative nine months ended Sept 30, 2019 (9MFY19), Pharmaniaga posted a 22.7% decline in net profit to RM29.38 million from RM38.03 million a year ago, on lower contribution margins. Revenue for 9MFY19, however, rose 17.7% to RM2.1 billion from RM1.79 billion for 9MFY18 on solid performances from both its concession and non-concession businesses.

It declared dividends of 8.5 sen, amounting to RM22.1 million, for FY19.
22/01/2020 2:39 PM
Victor Yong Buy when others are fearful :p

发马董事经理拿督法西拉的合约在3月31日结束后,将卸下这个担任长达9年的职位。
(吉隆坡21日讯)政府相关公司(GLC)高层撤职潮不断,发马(PHARMA,7081,主板医疗保健组)董事经理拿督法西拉的合约在3月31日结束后,将卸下这个担任长达9年的职位。

未公布新人选

发马并未公布新董事经理人选,但现任首席营运员莫哈末依克巴将暂代董事经理职务。

法西拉是在2011年4月1日出任发马董事经理,成功在9年任期内提高集团营业额56.8%,至23亿8500万令吉,但净利却倒退18.58%,至4250万令吉。

根据发马2018年常年报告,法西拉是在2001年成立Idaman Pharma私人有限公司,开始进军高度监管的制药领域。在她的领导下,Idaman Pharma成功与发马母公司——莫实得控股(BSTEAD,2771,主板工业产品服务组)发展战略结盟关系,并最终促使莫实得控股在2011年收购发马。

截至2019年2月28日,国防卫队基金局(LTAT)持有发马67.32%股权,为后者最大股东,其中56.09%贡献自莫实得控股。

自前主席丹斯里洛丁在2018年12月请辞后,发马董事部便频频出现变动。洛丁离职后,紧接着5名董事也先后离去,迫使集团先后委任拿督许福斐(音译)、拿督莫哈末扎希尔、拿督莫哈末沙龙等人接任董事职务。

业务方面,发马过去一年波折不断,政府在去年11月宣布在药物运输合约届满后,不再与发马续约,但后为免药物供应受到影响,决定给予25个月过渡期。

随后,发马也获得卫生部为期5年的合约,以为该部提供物流与分销服务。
22/01/2020 4:08 PM
Victor Yong Boustead Holdings Bhd is a Malaysia-based conglomerate. The company operates in six segments. The plantation division primarily involves the planting of oil palm and processing of crude palm oil. The heavy industries division primarily involves shipbuilding, fabrication of offshore structures, and vessel restoration and maintenance. The property division primarily involves real estate development and leasing, as well as hotel operation. The finance and investment division comprises the company's investing activities. The pharmaceutical division manufactures, trades, and markets pharmaceutical products. The trading and industrial division primarily operates a petrol station network and manufactures and trades building materials.
Date Close
22/01/2020 0.925
21/01/2020 0.925
20/01/2020 0.93
17/01/2020 0.935
16/01/2020 0.94
15/01/2020 0.945
14/01/2020 0.93
13/01/2020 0.935
10/01/2020 0.93
09/01/2020 0.92
08/01/2020 0.915
07/01/2020 0.94
06/01/2020 0.935
03/01/2020 0.96
02/01/2020 0.96
31/12/2019 0.95
30/12/2019 0.975
27/12/2019 0.945
26/12/2019 0.925
23/01/2020 9:16 AM
terence775 Finally threw away all my holdings of this company. I bought at over RM 2, thinking, hoping, believing, that the management can turn around. In the end, I decided this is a useless company and, despite more than 50% losses, I'll just bite the pain and move on. I pray everyone good luck and wealth wherever you all go.
06/02/2020 5:24 PM
Gala Kat Since PH came into power, what have these bunch of incompetent ' gaji buta ' morons up at the board shown or done to uplift the performance of the company ? Clearly, glorious days are over for this ' waiting to be spoon fed ' counter or rather ... parasite !
12/02/2020 12:25 PM
SuperPanda will buy this week below 90c, keep for 3 years will earn >100%
17/02/2020 11:27 PM
shpg22 Buy rubbish get punished applied for all badly managed company like Boustead.
19/02/2020 11:20 AM
SuperPanda same fate like FGV, local GLC problem with bribes/contracts issue, but for traders like us, buy low and sell high later, FGV those bought below 90c already profit a lot
19/02/2020 1:09 PM